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Recanalisation theraphy for acute 
ischemic stroke in cancer patients
Giovanni Merlino1,2,5*, Carmelo Smeralda2,3,5, Gian Luigi Gigli2,3, Simone Lorenzut1, 
Sara Pez2,3, Andrea Surcinelli2,3, Alessandro Marini2,3, Valentina Maniaci4 & 
Mariarosaria Valente2,3
To date, very few studies focused their attention on efficacy and safety of recanalisation therapy in 
acute ischemic stroke (AIS) patients with cancer, reporting conflicting results. We retrospectively 
analysed data from our database of consecutive patients admitted to the Udine University Hospital 
with AIS that were treated with recanalisation therapy, i.e. intravenous thrombolysis (IVT), 
mechanical thrombectomy (MT), and bridging therapy, from January 2015 to December 2019. We 
compared 3-month dependency, 3-month mortality, and symptomatic intracranial haemorrhage 
(SICH) occurrence of patients with active cancer (AC) and remote cancer (RC) with that of patients 
without cancer (WC) undergoing recanalisation therapy for AIS. Patients were followed up for 
3 months. Among the 613 AIS patients included in the study, 79 patients (12.9%) had either AC (n = 46; 
7.5%) or RC (n = 33; 5.4%). Although AC patients, when treated with IVT, had a significantly increased 
risk of 3-month mortality [odds ratio (OR) 6.97, 95% confidence interval (CI) 2.42–20.07, p = 0.001] 
than WC patients, stroke-related deaths did not differ between AC and WC patients (30% vs. 28.8%, 
p = 0.939). There were no significant differences between AC and WC patients, when treated with 
MT ± IVT, regarding 3-month dependency, 3-month mortality and SICH. Functional independence, 
mortality, and SICH were similar between RC and WC patients. In conclusion, recanalisation therapy 
might be used in AIS patients with nonmetastatic AC and with RC. Further studies are needed to 
explore the outcome of AIS patients with metastatic cancer undergoing recanalisation therapy.
Patients affected by cancer have an increased risk of acute ischemic stroke (AIS) due to comorbid vascular disease 
and  hypercoagulability1–5. Atherosclerosis, nonbacterial thrombotic endocarditis, disseminated intravascular 
coagulation, tumor embolism, and cerebral venous thrombosis represent the most frequent causes of AIS in 
cancer  patients6. In addition, concurrent cancer is able to impair short-term outcome in AIS  patients7. On the 
basis of these considerations, it is fundamental to improve knowledge regarding recanalisation therapy of AIS 
patients affected by cancer. Recently, a retrospective analysis of a large nationwide sample of inpatient hospi-
talizations from 1998 to 2015 showed that cancer patients with AIS received intravenous thrombolysis (IVT) 
about two thirds as often as AIS patients without cancer. Differently, use of mechanical thrombectomy (MT) was 
similar between patients with and without cancer during the study  period8.
To date, very few studies focused their attention on efficacy and safety of recanalisation therapy in AIS patients 
with cancer, reporting conflicting  results9–16. In addition, it is unknown whether the outcome of AIS patients with 
remote cancer (RC) is more similar to that of patients with active cancer (AC) or without cancer (WC). Hypoth-
esizing that AIS patients undergoing recanalisation therapy might have a different outcome on the basis of their 
cancer status, we decided to perform this study comparing AC and RC patients with those without malignancy.
Methods
Study participants. We retrospectively analysed data from our database of consecutive patients admitted 
to the Udine University Hospital with AIS that were treated with recanalisation therapy, i.e. IVT, and MT ± IVT, 
from January 2015 to December 2019. Patients were followed up for 3  months. Patients showing symptoms 
onset within 4.5 h received IVT (0.9 mg/kg over 1 h) in accordance with international  guidelines17,18. IVT was 
performed right after the native CT-scan if intracerebral haemorrhage (ICH) had been ruled out. Patients were 
considered eligible for MT if the following inclusion criteria were fulfilled: (1) presence of large vessel occlusion 
(LVO) in the anterior (intracranial internal carotid artery, anterior cerebral artery, middle cerebral artery, and 
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extracranial internal carotid artery plus middle cerebral artery, i.e. tandem occlusion) or posterior (intracranial 
vertebral artery, basilar artery, and posterior cerebral artery) circulation as revealed by CT angiography (CTA); 
(2) symptoms onset within 6 h; (3) Alberta stroke program early CT score (ASPECTS) > 6 on direct CT  scan19. 
Alteplase administration was continued until the angiographic suite would be ready and during the endovas-
cular procedure. Patients presenting beyond the time window for IVT or with major contraindications to IVT 
underwent direct  MT18. All patients treated with recanalisation therapy were re-scanned approximately 24 h 
after treatment, or sooner if there was clinical deterioration.
Based on a previous study by Masrur et al.9, our patients were classified according to their cancer history into 
those with AC, RC, and WC. AC patients were those with any current or previous metastatic disease (except 
brain metastases), those undergoing current treatment for a malignancy or those who were offered treatment but 
refused it. Patients were also considered as affected by AC when initial diagnosis of malignancy was made during 
hospitalization after the onset of AIS. RC patients were those whose records indicated an inactive past history of 
malignancy with no history or evidence of metastatic disease, and who had completed any planned treatments. 
After the end of treatment, the period of 1 year was used for defining the absence of evidence of active cancer. 
Patients with end-stage malignancy, i.e. subjects with a life expectancy of less than 6-months or who received pal-
liative care, and those with metastatic brain lesions are not treated with recanalisation therapy at our institution.
Written informed consent was obtained from all patients or their representatives. The study was approved 
by the local ethics committee, Comitato Etico Unico Regionale (Ref. No. CEUR-2020-Os-173). All experimental 
protocols were approved by the local ethics committee, Comitato Etico Unico Regionale. All research was per-
formed in accordance with relevant guidelines/regulations.
Data collection. The following variables were collected: age, sex, vascular risk factors, laboratory findings, 
admission systolic and diastolic blood pressure, admission heart rate and previous pharmacological treatment. 
In addition, early ischemic changes on native CT-scan within the middle cerebral artery were graded according 
to the  ASPECTS19. Regarding vascular risk factors, we adopted the following definitions: (1) previous transient 
ischemic attack/stroke was defined if the patient had a history of ischemic (transient attack or stroke) or haemor-
rhagic cerebrovascular disease; (2) the presence of cardiovascular disease was based on the history of previous 
ischemic heart disease and/or revascularization treatment using percutaneous coronary intervention/coronary 
artery bypass grafting; (3) atrial fibrillation was defined if the patient had past medical history of atrial fibrilla-
tion that had been confirmed in medical records; (4) high blood pressure was defined as the history of hyper-
tension and/or use of antihypertensive medication; (5) a history of diabetes mellitus that had been confirmed 
in medical records and/or use of insulin/oral hypoglycaemic agents were considered for defining diabetes; (6) a 
presence of hypercholesterolemia was based on the use of lipid-lowering medications; (7) information on active 
tobacco use was used for defining patient as a current smoker. For laboratory tests, venous blood samples were 
drawn at our Neurology Unit, within 24 h after hospitalization, during the morning hours (range 06.00–08:00) 
after an overnight fast (at least 12 h).
Regarding malignancy, we collected information on: (1) type of cancer; (2) metastasis status; (3) modality of 
treatment; (4) impact of cancer on patient’s daily living abilities by means of the Eastern Cooperative Oncology 
Group (ECOG) performance score. The ECOG score ranges from zero (“fully active”) through three (”capable 
of only limited self-care”) to five (“dead”)20. Based on previous  studies21,22, we classified our AC patients into 
those with ECOG score 0–1 versus those with score ≥ 2. Information on underlying causes of death was collected.
Clinical assessment. The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification was used 
to determine AIS subtypes based on their  etiology23. The National Institute of Health Stroke Scale (NIHSS) score 
was adopted for determining stroke severity at admission and at discharge. Patients showing an improvement 
of ≥ 8 points on the NIHSS from baseline or a NIHSS score of 0 or 1 at discharge were considered as affected 
by major neurological improvement. Functional outcome was assessed by means of the modified Rankin Scale 
(mRS) at admission, based on pre-stroke disability, and 3 months after stroke. The mRS score after discharge was 
recorded at the patients’ routine clinical visit or through telephone interview with patients or their immediate 
caregivers. Patients with a mRS score comprised between 3 and 5 were considered functionally dependent. The 
presence of intracranial haemorrhage (ICH), as a consequence of the recanalisation therapy, was defined as any 
parenchymal hematoma (PH) based on the European Cooperative Acute Stroke Study (ECASS) morphologic 
definitions (ECASS PH-1 or PH-2)24, whereas presence of symptomatic intracranial haemorrhage (SICH) was 
based on the ECASS-III  protocol25. Regarding recanalisation therapy, we collected information on: (1) time from 
symptom onset to IVT or MT; (2) time from hospital arrival to alteplase administration (door-to-needle time); 
(3) time from hospital arrival to groin puncture (door-to-groin time); (3) MT procedure duration; (4) recana-
lisation rate, assessed at the end of MT using the thrombolysis in cerebral infarction (TICI) classification and 
defined as successful recanalisation when a TICI 2b-3 was achieved.
Outcome measures. The following primary endpoints were analysed: (1) 3-month dependency; (2) 
3-month all-cause mortality; (3) presence of SICH. Secondary endpoints were: (1) no major neurological 
improvement at discharge; (2) in-hospital all-cause mortality; (3) presence of ICH. All the outcome measures 
were collected as part of our routine clinical practice in patients affected by cerebrovascular events.
Statistical analysis. Data are displayed in tables as mean and standard deviation, if not otherwise specified.
Differences across the different groups were assessed by means of the Chi square test for categorial vari-
ables. One-way analysis of variance for normally distributed continuous variables, and the Kruskal–Wallis test 
for non-normally distributed continuous variables and for ordinal variables were used. Post-hoc analysis was 
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performed by means of the Bonferroni test or the Dunn test, when appropriate. The Kolmogorov–Smirnov test 
with Lilliefors significant correction was used to assess normal distribution of data.
Rates of primary and secondary endpoints were separately calculated for patients receiving IVT and for those 
undergoing MT ± IVT.
The impact of cancer status on primary outcome measures was evaluated by multiple logistic regression analy-
sis with WC patients as reference category both in patients receiving IVT and in those undergoing MT ± IVT. 
Age, baseline NIHSS score, and pre-stroke mRS were included in the model as potential confounding variables. 
Systolic blood pressure was added to other confounders in the analysis that evaluated the association between 
cancer status and SICH occurrence.
All probability values are two-tailed. A p value < 0.05 was considered statistically significant. Statistical analysis 
was carried out using the SPSS Statistics, Version 22.0 (Chicago, IL, USA).
Results
Baseline characteristics. During the study period 2037 patients were admitted for AIS, of them 755 
were treated with recanalisation therapy. We lost to follow-up 142 patients (18.8%), thus the remaining 613 
AIS patients were included in the study. Of them, 440 (71.8%) were treated with IVT, and 173 with MT, i.e. 
114 (18.6%) received MT combined with alteplase, and 59 (9.6%) undergoing direct MT. Seventy-nine patients 
(12.9%) had either AC (n = 46; 7.5%) or RC (n = 33; 5.4%). These data are summarised in the flow diagram of 
the study (see Fig. 1). Clinical characteristics of AC patients are reported in Table 1. An ECOG score of 0–1 was 
observed in 43 (93.5%) AC patients. None among cancer patients presented AIS during a hospitalization for the 
malignancy. Types of cancer in RC patients were the following: prostate cancer in eight patients (24.2%); breast 
cancer in seven patients (21.2%); non-Hodgkin lymphoma in four patients (12.1%); endometrial cancer in three 
patients (9.1%); penile cancer in three patients (9.1%); kidney cancer in two patients (6.1%); laryngeal cancer in 
two patients (6.1%); urothelial cancer in two patients (6.1%); gastric cancer in one patient (3%); lung cancer in 
one patient (3%).
The general characteristics of the three groups are presented in Table 2. Regarding baseline demographic and 
clinical characteristics, our groups did not show significant differences. In particular, age, sex, and vascular risk 
factors did not differ among the three groups. Apart from the protein level that was significantly lower in AC 
patients than in WC ones (p = 0.045, Bonferroni post-hoc test), the other laboratory findings were similar among 
groups. Although there was a trend for higher levels of C-reactive protein in AC patients, the prevalence of active 
infections was similar between the three groups (AC: 2.2%; RC: 3%; WC: 2.8%, p = 0.8). Causes of stroke, as 
classified by means of the TOAST, severity of neurological impairment at admission, as measured by the NIHSS 
score, and rate of pre-stroke functional independence, defined as an mRS ≤ 2, were not different among AC, RC, 
and WC patients. Although AC patients were treated more commonly with MT, alone or combined with IVT, 
than those in RC and WC groups, this difference was not statistically significant. Time from symptoms onset 
to recanalisation therapy, door-to-needle time, door-to-groin time, length of MT procedure, and successful 
recanalisation rate after MT were comparable among the three groups.
Association of cancer status with clinical outcomes among patients receiving IVT (univariate 
analysis). Figures 2, 3, and 4 report rates of primary outcomes according to cancer status among patients 
receiving IVT. Prevalence of no major neurological improvement (48% for AC, 32% for RC, and 43.3% for WC, 
p = 0.471), in-hospital mortality (12% for AC, 8% for RC, and 5.6% for WC, p = 0.405), and ICH (20% for AC, 4% 
for RC, and 10.3% for WC, p = 0.168) was not statistically different among the three groups.
Although 3-month mortality was significantly increased in AC patients, we observed that stroke-related 
deaths were similar between these patients and WC ones (30% vs. 28.8%, p = 0.939). Causes of death, other than 
stroke, in AC patients were the following: sepsis (n = 3), and cancer progression (n = 3).
Whereas metastatic AC patients showed higher rates of 3-month mortality (55.6% vs. 14.6%, p = 0.017), 
functional dependency (50% vs. 42.9%, p = 0.593), and SICH (0% vs. 7.3%, p = 0.544) did not differ between 
patients with metastatic and non-metastatic AC.
Association of cancer status with clinical outcomes among patients undergoing MT ± IVT 
(univariate analysis). Rates of primary outcomes according to cancer status among patients treated with 
MT ± IVT are reported in Figs. 5, 6, and 7. Whereas prevalence of no major neurological improvement (55% for 
AC, 62.5% for RC, and 36.6% for WC, p = 0.120) and in-hospital mortality (9.5% for AC, 25% for RC, and 10.4% 
for WC, p = 0.427) was similar, rates of ICH were statistically different among the three groups (52.4% for AC, 
37.5% for RC, and 22.9% for WC, p = 0.014).
Among patients undergoing MT ± IVT, stroke-related deaths were significantly less common in AC subjects 
than in WC ones (14.3% vs. 69.6%, p = 0.015). Causes of death, other than stroke, in AC patients were the fol-
lowing: sepsis (n = 4), cancer progression (n = 1), and epigastric artery rupture (n = 1).
Prevalence of 3-month dependency (75% vs. 33.3%, p = 0.177), 3-month mortality (20% vs. 37.5%, p = 0.424), 
and SICH (20% vs. 4.2%, p = 0.320) did not differ between patients with metastatic and non-metastatic AC.
Association of cancer status with clinical outcomes among patients receiving IVT (multivari-
ate analysis). As reported in Table 3, AC patients had a significantly higher risk of 3-month mortality than 
WC ones, even when multivariate analysis was performed. In contrast, the univariate association between the 
presence of AC and SICH occurrence was not confirmed after controlling for confounders. Independent pre-
dictors of the primary endpoints were the following: (1) age [odds ratio (OR) 1.04, 95% confidence interval 
(CI) 1.02–1.07, p = 0.001] and NIHSS score at admission (OR 1.15, 95% CI 1.10–1.20, p = 0.001) for 3-month 
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dependency; (2) Age (OR 1.07, 95% CI 1.04–1.11, p = 0.001), and NIHSS score at admission (OR 1.15, 95% CI 
1.10–1.20, p = 0.001) for 3-month all-cause mortality; (3) NIHSS score at admission (OR 1.04, 95% CI 1.02–1.11, 
p = 0.05) for SICH.
Association of cancer status with clinical outcomes among patients undergoing MT ± IVT (mul-
tivariate analysis). Odds of functional dependency, mortality, and SICH did not differ between AC and 
WC patients in multivariate analysis (see Table 4). Independent predictors of the primary endpoints were the 
following: (1) age (OR 1.04, 95% CI 1.01–1.07, p = 0.04) for 3-month dependency; (2) age (OR 1.06, 95% CI 
1.01–1.11, p = 0.02), and pre-stroke mRS 0–2 (OR 0.15, 95% CI 0.03–0.68, p = 0.01) for 3-month all-cause mor-
tality; (3) NIHSS score at admission (OR 1.10, 95% CI 1.07–1.25, p = 0.04) for SICH.














Patients admitted with AIS from January 
2015 to December 2019
(n = 2037)
Patients with AIS not treated with 
recanalisation therapy
(n = 1282)
Figure 1.  Flow diagram of the study. AIS acute ischemic stroke, IVT intravenous thrombolysis, MT mechanical 
thrombectomy, AC active cancer, RC remote cancer, WC without cancer.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:11634  | https://doi.org/10.1038/s41598-021-91257-5
www.nature.com/scientificreports/
Discussion
This study demonstrated that AC patients affected by AIS did not have a worse outcome than WC subjects when 
treated with recanalisation treatment. Although rates of 3-month all-cause mortality were significantly higher in 
AC patients than in WC ones, when treated with IVT, we observed that stroke-related deaths were uncommon 
in AC subjects. Similarly, cancer status did not affect disability, mortality, and cerebral haemorrhagic complica-
tions in AIS patients undergoing MT ± IVT. In addition, clinical outcomes of RC and WC patients did not differ, 
regardless of treatment modalities for AIS.
To date, only few studies investigated the efficacy and safety of recanalisation therapy in AIS patients affected 
by cancer. In particular, data are very limited both for AC subjects and for RC ones. The largest investigations were 
performed by Murthy et al. and Weeda et al. who used the International Classification of Disease (ICD) codes for 
detecting cancer patients affected by  AIS10,13. Although these studies included 32,576 and 13,993 patients, they 
suffered from major limitations: (1) information on stroke severity, stroke subtype, 90-day functional outcome, 
cancer staging, and modality of cancer treatment was lacking; (2) the use of administrative data for research 
depends largely on its accuracy and reliability, thus coding errors were a possibility.
Prevalence of 3-month dependency did not differ between AC and WC patients, regardless of treat-
ment modalities for AIS. A previous Italian study by Sallustio et al. reported similar  results14. Except for two 
researches conducted in Asian patients undergoing  MT12,15, the remaining literature agreed that, in AIS patients 
undergoing recanalisation therapy, functional independence was not affected by the presence of concurrent 
 malignancy9,11,14,16.
In 2011 Masrur et al. reviewed their database of AIS patients treated with urgent reperfusion treatment. Of 308 
subjects included into the study, 18 and 26 were affected by active and remote malignancy, respectively. Patients 
with active malignancy had higher in-hospital mortality, but were more likely to die due to medical comorbidities 
instead of stroke-related  causes9. More recently, prevalence of 3-month mortality has been reported more than 
double in patients with active malignancy with respect to controls in the case–control study of Sallustio et al. 
(29.1% vs. 12.5%). However, the most common causes of death were cancer-related and not stroke-related14. 
The above reported data are perfectly in line with our results. In fact, rates of 3-month mortality were higher 
in AC patients than in WC ones. However, stroke-related deaths were quite uncommon in patients with active 
malignancy, occurring in 30% of patients receiving IVT and in 14.6% of patients undergoing MT ± IVT. This 
lower stroke-related mortality was certainly not attributable to an earlier recognition and treatment of stroke in 
AC because of pre-existing hospitalization, since all AC patients were not hospitalized at the time of their stroke. 
Confirming this statement, rates of in-hospital mortality, that is in strong relationship with stroke consequences, 
were not different between AC and WC patients, regardless of treatment modalities for AIS. Why AC patients 
treated with MT ± IVT for AIS had lower rates of stroke-related deaths than WC ones remains unknown. Further 
studies should investigate this specific topic.
The risk of SICH after IVT and MT varies from 2 to 7%26,27. Coagulopathy and consequences of radiotherapy 
or chemotherapy may increase the odds of haemorrhage transformation after recanalisation therapy in AIS 
patients with active  malignancy28. Data on SICH prevalence in AC patients show an extremely wide range from 
0 to 16.2%14,16. This is because SICH definitions were different among studies. Only Sallustio et al. used our SICH 
definition based on the ECASS-III protocol. Whereas these authors did not report any SICH in both AC patients 
and controls, we observed a prevalence of 12% in patients with concurrent malignancy who received IVT and 
9.5% in those who underwent MT ±  IVT14. Methodological differences between the two studies might explain 
the discrepancy between our data and those of Sallustio et al.14. In our experience SICH occurrence did not 
differ between the three groups of AIS patients undergoing MT ± IVT, differently SICH was significantly more 
common in our AC patients, when treated with IVT, than in the other two groups. This univariate association 
was not confirmed when confounders, i.e. age, baseline NIHSS score, pre-stroke mRS, and admission systolic 
blood pressure, were included in the multivariate model. NIHSS at admission represented the only independent 
predictor of SICH in both IVT and MT ± IVT patients. Thus, it seems that AC patients treated with IVT have 
Table 1.  Clinical characteristics of patients with active cancer.
Cancer type No. (%) (n = 46) Metastatic, No. (%) (n = 14) Current cancer treatment, No. (%) (n = 14)
Breast 7 (15.2) 0 5/7 (71.4)
Colorectal 7 (15.2) 3/7 (42.9) 1/7 (14.3)
Prostate 7 (15.2) 1/7 (14.3) 5/7 (71.4)
Lung 6 (13) 3/6 (50) 0
Urothelial 6 (13) 1/6 (16.7) 1/6 (16.7)
Neuroendocrine 3 (6.5) 2/3 (66.7) 0
Kidney 2 (4.3) 1/2 (50) 1/2 (50)
Liver 2 (4.3) 0 0
Unknown primary site 2 (4.3) 2/2 (100) 0
Atrial myxoma 1 (2.2) 0 0
Endometrial 1 (2.2) 0 0
Multiple myeloma 1 (2.2) N/A 0
Pancreas 1 (2.2) 1/1 (100) 1/1 (100)
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AC (n = 46) RC (n = 33) WC (n = 534) p
Demographic data
Age, years 73.2 ± 11.2 74.4 ± 11.1 72.5 ± 13.1 0.665
Males, n (%) 25 (54.3) 19 (57.6) 289 (54.1) 0.928
Vascular risk factors
Previous TIA/stroke, n (%) 6 (13) 1 (3) 53 (9.9) 0.321
Cardiovascular disease, n (%) 4 (8.7) 7 (21.2) 77 (14.4) 0.292
Atrial fibrillation, n (%) 9 (19.6) 8 (24.2) 97 (18.2) 0.674
Hypertension, n (%) 33 (71.7) 26 (78.8) 354 (66.3) 0.267
Diabetes mellitus, n (%) 7 (15.2) 6 (18.2) 93 (17.4) 0.922
Hypercholesterolemia, n (%) 15 (32.6) 14 (42.4) 133 (24.9) 0.053
Current smoking, n (%) 8 (17.4) 5 (15.2) 74 (13.9) 0.794
Laboratory findings
Hb, g/dl 12.8 ± 1.8 13.5 ± 1.5 13.1 ± 1.7 0.151
Platelets,  103/mm3 186.5 ± 65 186.8 ± 40.3 205.4 ± 60.2 0.052
aPTT ratio* 0.95 (0.88–1.04) 0.93 (0.86–1.07) 0.95 (0.87–1.08) 0.897
INR* 1.06 (1.01–1.11) 1.04 (1–1.16) 1.06 (1–1.14) 0.868
C-reactive protein, mg/l* 9.89 (2.57–14.35) 3.11 (1.28–9.04) 4.37 (1.95–11.68) 0.059
Protein, g/dl 6 ± 0.6 6.3 ± 0.4 6.2 ± 0.6 0.045
Albumin, g/dl 3.6 ± 0.4 3.6 ± 0.3 3.7 ± 0.4 0.312
Glucose, mg/dl* 124.5 (105.2–144.5) 115 (106–137) 126 (109–155) 0.181
eGFR, ml/mina 84.6 ± 20.9 84.1 ± 26.1 78.3 ± 24 0.111
Total cholesterol, mg/dl* 164 (138–190) 164 (139–193) 172 (146–200) 0.723
HDL cholesterol, mg/dl 51.5 ± 17.8 51.1 ± 14.6 52.9 ± 15.9 0.723
LDL cholesterol, mg/dl 94.9 ± 31.1 96.8 ± 34.8 100.3 ± 37.4 0.594
Triglycerides, mg/dl* 88 (70–131) 102 (79–135) 93 (67.5–126) 0.691
Blood pressure and heart rate
Systolic blood pressure, mmHg 157.8 ± 22.8 163 ± 27 157.1 ± 24.9 0.447
Diastolic blood pressure, mmHg 89.2 ± 13.5 90.2 ± 14.7 86.6 ± 15.1 0.273
Heart rate, min 76.2 ± 15 77.4 ± 14.1 78.3 ± 15.7 0.716
Antithrombotic treatment at admission 0.646
Antiplatelets, n (%) 15 (32.6) 15 (45.5) 180 (33.7)
Anticoagulants, n (%) 2 (4.3) 2 (6.1) 37 (6.9)
Median baseline ASPECTS (range) 10 (8–10) 10 (8–10) 10 (7–10) 0.901
Stroke subtypes based on TOAST classification 0.692
Large arterial atherosclerosis, n (%) 5 (10.9) 7 (21.2) 83 (15.5)
Cardioembolism, n (%) 21 (45.7) 14 (42.4) 209 (39.1)
Small vessel occlusion, n (%) 3 (6.5) 4 (12.1) 48 (9)
Other determined etiology, n (%) 0 0 14 (2.6)
Undetermined etiology, n (%) 17 (37) 8 (24.2) 180 (33.7)
Baseline clinical characteristics
Median NIHSS score at admission (IQR) 12.5 (6–20) 9 (5–17) 9 (5–18) 0.128
Median NIHSS score at discharge (IQR) 3.5 (0.2–10) 1 (0–8.5) 2 (0–8) 0.318
Pre-stroke mRS 0–2, n (%) 43 (93.5) 31 (93.9) 480 (89.9) 0.566
Type of recanalization therapy 0.089
IVT, n (%) 24 (54.3) 25 (75.8) 390 (73)
MT + IVT, n (%) 13 (28.3) 6 (18.2) 95 (17.8)
MT, n (%) 8 (17.4) 2 (6.1) 49 (9.2)
Other information on recanalization therapy
Time from symptoms onset to IVT, min 172 ± 57.3 180.3 ± 59.9 164.5 ± 49.5 0.063
Time from symptoms onset to MT, min 191 ± 46.8 215 ± 37.2 213.5 ± 70.3 0.456
Door-to-needle time, min 76.2 ± 15 77.4 ± 14.1 78.3 ± 15.7 0.257
Door-to-groin time, min* 123.5 (105.7–143.2) 112.5 (85.5–137.2) 105 (80–135) 0.281
MT procedure length, min 79.9 ± 36.2 72.5 ± 35.5 77.1 ± 38.9 0.892
TICI 2b-3 after MT, n (%) 15 (71.4) 5 (62.5) 119 (82.6) 0.207
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Table 2.  General characteristics of the subjects according to the cancer status. Data are presented as mean 
and standard deviation for normally distributed continuous variables. Non-normally distributed continuous 
variables are displayed as median and interquartile range and are identified by an asterisk (*). AC active cancer, 
RC remote cancer, WC without cancer, TIA transient ischemic attack, Hb haemoglobin, aPTT activated partial 
thromboplastin time, INR international normalised ratio, eGFR estimated glomerular filtration rate, HDL 
high-density lipoprotein, LDL low-density lipoprotein, ASPECTS Alberta stroke program early CT score, 
NIHSS National Institute of Health stroke scale, IQR interquartile range, mRS modified Rankin scale, IVT 
intravenous thrombolysis, MT mechanical thrombectomy, TICI thrombolysis in cerebral infarction. a eGFR was 
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Figure 2.  Rates of 3-month dependency according to cancer status among patients receiving IVT. IVT 
















Figure 3.  Rates of 3-month all-cause mortality according to cancer status among patients receiving IVT. IVT 
intravenous thrombolysis, AC active cancer, RC remote cancer, WC without cancer.
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more haemorrhages because they have more severe stroke. These findings agreed with previous studies that did 
not report any significant association between the presence of active malignancy and the occurrence of haemor-
rhagic transformation after recanalisation  therapy9–11,14,16.
A recent study by Yoo et al. compared 223 patients with nonactive cancer, 105 patients with active nonmeta-
static cancer, and 140 patients with metastases. Since presence of metastases increased more than four times the 
risk of mortality, the authors suggested of using a careful approach when considering recanalisation therapy for 
AIS in patients with metastases. Similarly, we reported higher rates of 3-month mortality in patients with meta-
static AC, but only when they were treated with IVT. In fact, we did not observe any significant difference regard-
ing 3-month dependency, 3-month mortality, and SICH between patients with metastatic and non-metastatic AC 
when subjects underwent MT. These partial discrepancies might be due to the fact that, differently from our study, 
Yoo et al. enrolled patients not only treated, but also not treated with recanalisation therapy and used a longer 
follow-up period (6 months vs. 3 months)29. However, our results on metastatic patients should be considered 











Figure 4.  Rates of SICH according to cancer status among patients receiving IVT. SICH symptomatic 















Figure 5.  Rates of 3-month dependency according to cancer status among patients undergoing MT ± IVT. MT 
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Findings on efficacy and safety of recanalisation therapy in AIS patients with remote malignancy are very 
limited. Only Masrur et al. investigated this specific topic showing that RC patients had an unfavourable out-
come. Rates of SICH were higher in RC patients than in AC and WC ones and in-hospital mortality did not 
differ between RC and AC  patients9. Our patients with nonactive, remote malignancy receiving IVT had good 
clinical outcomes. Indeed, functional independence, mortality, and haemorrhagic transformation were similar 
between RC and WC patients. Although we did not observe any significant difference, RC patients undergoing 
MT showed higher rates of 3-month dependency, 3-month mortality, and in-hospital mortality than WC ones. 
We should underline that AIS patients enrolled by Masrur et al. received IVT within 3 h of stroke onset and 
were treated with intra-arterial thrombolysis when LVO occurred. Our data clearly support to use IVT in AIS 
patients with RC who should be considered as individuals with no previous history of malignancy. Additional 
data regarding MT in RC patients are needed.
Although the present study was one of the largest studies investigating outcome of cancer patients undergoing 
recanalisation therapy for AIS, nevertheless, it has some important limitations that merit mention. (1) This study 
















Figure 6.  Rates of 3-month all-cause mortality according to cancer status among patients undergoing 











Figure 7.  Rates of SICH according to cancer status among patients undergoing MT ± IVT. SICH symptomatic 
intracranial haemorrhage, MT mechanical thrombectomy, IVT intravenous thrombolysis, AC active cancer, RC 
remote cancer, WC without cancer.
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included. We cannot exclude that some cancer patients were not assigned for recanalisation due to their advanced 
malignant disease and consequently they were not included in the study; (2) this is an observational study per-
formed in a single centre with a limited sample size, which could have resulted in insufficient statistical power 
to detect true differences between groups; in fact, a power analysis was not conducted before data collection; 
(3) even after controlling for known confounders, residual confounding from unobserved factors might have 
affected our results; (4) due to the retrospective nature of the study, new or recurrent unrecognized malignancies 
might have occurred in RC patients causing a misdiagnosis (RC instead of AC); (5) since some of the 3-month 
mRS scores were indirectly recorded through telephone interview with patients or their caregivers, it might be 
possible that post-discharge functional status was not captured as well as in-hospital one; (6) finally, differently 
from patients treated with MT, for whom recanalisation outcomes are given (measured as TICI result), we were 
unable to report data on recanalisation rate among patients receiving IVT alone.
In conclusion, recanalisation therapy might be used in AIS patients with cancer. In particular, IVT, and 
MT ± IVT, seem to be safe and effective methods of treatment in subjects with nonmetastatic, active cancer and 
with nonactive, remote cancer. Regarding metastatic patients, further studies with larger sample size are needed 
to explore the real outcome of AIS patients with metastatic cancer undergoing recanalisation therapy. Until then, 
an individualized approach considering life-expectancy is warranted in this subset of patients.
Data availability
The datasets used and analysed during the current study are available from the corresponding author on reason-
able request.
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